Trial · NCT02222688
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Tolerated Dose (MTD) or Biologically Active Dose of Cirmtuzumab | All Participants | 20 | mg/kg | ||
| Rate of Dose Limiting Toxicities (DLTs) | Cirmtuzumab 0.015 - 0.03 mg/kg | 0 | Occurrence of DLTs | ||
| Rate of Dose Limiting Toxicities (DLTs) | Cirmtuzumab 0.06 - 0.12 - 0.24 mg/kg | 0 | Occurrence of DLTs | ||
| Rate of Dose Limiting Toxicities (DLTs) | Cirmtuzumab 0.5 - 1.0 mg/kg | 0 | Occurrence of DLTs | ||
| Rate of Dose Limiting Toxicities (DLTs) | Cirmtuzumab 2.0 - 4.0 mg/kg | 0 | Occurrence of DLTs | ||
| Rate of Dose Limiting Toxicities (DLTs) | Cirmtuzumab 8 mg/kg | 0 | Occurrence of DLTs | ||
| Rate of Dose Limiting Toxicities (DLTs) | Cirmtuzumab 16 mg/kg | 0 | Occurrence of DLTs | ||
| Rate of Dose Limiting Toxicities (DLTs) | Cirmtuzumab 20 mg/kg | 0 | Occurrence of DLTs | ||
| Safety and Tolerability of UC-961 by Ongoing Evaluation of AEs. | Cirmtuzumab 0.015 - 0.03 mg/kg | 20 | Treatment emergent AEs | ||
| Safety and Tolerability of UC-961 by Ongoing Evaluation of AEs. | Cirmtuzumab 0.06 - 0.12 - 0.24 mg/kg | 37 | Treatment emergent AEs | ||
| Safety and Tolerability of UC-961 by Ongoing Evaluation of AEs. | Cirmtuzumab 0.5 - 1.0 mg/kg | 15 | Treatment emergent AEs | ||
| Safety and Tolerability of UC-961 by Ongoing Evaluation of AEs. | Cirmtuzumab 2.0 - 4.0 mg/kg | 31 | Treatment emergent AEs | ||
| Safety and Tolerability of UC-961 by Ongoing Evaluation of AEs. | Cirmtuzumab 8 mg/kg | 17 | Treatment emergent AEs | ||
| Safety and Tolerability of UC-961 by Ongoing Evaluation of AEs. | Cirmtuzumab 16 mg/kg | 34 | Treatment emergent AEs | ||
| Safety and Tolerability of UC-961 by Ongoing Evaluation of AEs. | Cirmtuzumab 20 mg/kg | 46 | Treatment emergent AEs | ||
| Clinical Activity Determined by the International Working Group in CLL (iwCLL) Criteria | Cirmtuzumab 0.015 - 0.03 mg/kg | Stable Disease | 0 | participants | |
| Clinical Activity Determined by the International Working Group in CLL (iwCLL) Criteria | Cirmtuzumab 0.06 - 0.12 - 0.24 mg/kg | Stable Disease | 0 | participants | |
| Clinical Activity Determined by the International Working Group in CLL (iwCLL) Criteria | Cirmtuzumab 0.5 - 1.0 mg/kg | Stable Disease | 1 | participants | |
| Clinical Activity Determined by the International Working Group in CLL (iwCLL) Criteria | Cirmtuzumab 2.0 - 4.0 mg/kg | Stable Disease | 0 | participants | |
| Clinical Activity Determined by the International Working Group in CLL (iwCLL) Criteria | Cirmtuzumab 8 mg/kg | Stable Disease | 1 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02222688/results